Molecular Biomarkers of Sessile Serrated Adenoma/Polyps

OBJECTIVES: Sessile serrated adenoma/polyps (SSA/Ps) contribute up to 30% of all colon cancers. There is considerable histological overlap between SSA/Ps and hyperplastic polyps. Inadequate consensus exists among pathologists, and no molecular biomarkers exist to differentiate these lesions with high accuracy. Lack of reliable diagnosis adversely affects clinical care. We previously defined a novel 7-gene panel by RNA sequencing that differentiates SSA/Ps from hyperplastic polyps. Here, we use the 7-gene panel as a molecular approach to differentiate SSA/Ps and HPs with higher sensitivity and specificity in a large sample set from a tertiary health care center. METHODS: Reverse transcription quantitative polymerase chain reaction of the 7-gene panel was performed on 223 formalin-fixed, paraffin-embedded serrated polyp and normal colon samples. We compare the sensitivity and specificity of the 7-gene panel with the BRAF and KRAS mutation incidence in differentiating SSA/Ps and HPs. We also evaluate the clinical data of patients with SSA/Ps showing high and low expression of the gene panel. RESULTS: The 7-gene RNA expression panel differentiates SSA/Ps and HPs with 89.2% sensitivity and 88.4% specificity. The gene panel outperforms BRAF mutation in identification of SSA/Ps. Clinical data suggest that expression of the 7-gene panel correlates with the development of SSA/Ps in the future. DISCUSSION: This study describes a novel 7-gene panel that identifies SSA/Ps with improved accuracy. Our data show that RNA markers of SSA/Ps advance the distinction of serrated lesions and contribute to the study of the serrated pathway to colon cancer.

[1]  H. Ashktorab,et al.  Molecular Characterization of sessile serrated adenoma/polyps from a large African American cohort. , 2019, Gastroenterology.

[2]  Seth D. Crockett,et al.  Variation in Pathologist Classification of Colorectal Adenomas and Serrated Polyps , 2018, The American Journal of Gastroenterology.

[3]  F. Bishehsari,et al.  Presence of small sessile serrated polyps increases rate of advanced neoplasia upon surveillance compared with isolated low-risk tubular adenomas. , 2016, Gastrointestinal endoscopy.

[4]  E. Dekker,et al.  Prevalence, distribution and risk of sessile serrated adenomas/polyps at a center with a high adenoma detection rate and experienced pathologists , 2016, Endoscopy.

[5]  M. Bronner,et al.  Gene Signature in Sessile Serrated Polyps Identifies Colon Cancer Subtype , 2016, Cancer Prevention Research.

[6]  D. Robertson,et al.  Interval Colorectal Cancer After Colonoscopy: Exploring Explanations and Solutions , 2015, The American Journal of Gastroenterology.

[7]  A. Sepulveda,et al.  Molecular and histologic considerations in the assessment of serrated polyps. , 2015, Archives of pathology & laboratory medicine.

[8]  F. Chan,et al.  Association between serrated polyps and the risk of synchronous advanced colorectal neoplasia in average‐risk individuals , 2015, Alimentary pharmacology & therapeutics.

[9]  M. O'brien,et al.  Colorectal serrated pathway cancers and precursors , 2015, Histopathology.

[10]  I. Nagtegaal,et al.  Defined morphological criteria allow reliable diagnosis of colorectal serrated polyps and predict polyp genetics , 2014, Virchows Archiv.

[11]  B. Leggett,et al.  Critical Appraisal of the Diagnosis of the Sessile Serrated Adenoma , 2014, The American journal of surgical pathology.

[12]  Reiko Nishihara,et al.  Long-term colorectal-cancer incidence and mortality after lower endoscopy. , 2013, The New England journal of medicine.

[13]  N. Cho,et al.  Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location , 2013, British Journal of Cancer.

[14]  Melissa Wright,et al.  Interobserver agreement in the reporting of colorectal polyp pathology among bowel cancer screening pathologists in Wales , 2013, Histopathology.

[15]  J. Potter,et al.  Genomic aberrations occurring in subsets of serrated colorectal lesions but not conventional adenomas. , 2013, Cancer Research.

[16]  Florian Markowetz,et al.  Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions , 2013, Nature Medicine.

[17]  Charles J. Kahi,et al.  Serrated Lesions of the Colorectum: Review and Recommendations From an Expert Panel , 2012, The American Journal of Gastroenterology.

[18]  Douglas K Rex,et al.  Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. , 2012, Gastroenterology.

[19]  John D Potter,et al.  BRAF Mutation Status and Survival after Colorectal Cancer Diagnosis According to Patient and Tumor Characteristics , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[20]  M. Mäkinen,et al.  Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma , 2011, Histopathology.

[21]  J. Cubiella,et al.  5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. , 2011, Gastroenterology.

[22]  Charles J. Kahi,et al.  The American Society for Gastrointestinal Endoscopy PIVI (Preservation and Incorporation of Valuable Endoscopic Innovations) on real-time endoscopic assessment of the histology of diminutive colorectal polyps. , 2011, Gastrointestinal endoscopy.

[23]  P. Conesa‐Zamora,et al.  Clinicopathologic study of 85 colorectal serrated adenocarcinomas: further insights into the full recognition of a new subset of colorectal carcinoma. , 2010, Human pathology.

[24]  J. Bond,et al.  CIMP Status of Interval Colon Cancers: Another Piece to the Puzzle , 2010, The American Journal of Gastroenterology.

[25]  N. Shepherd,et al.  Observer agreement in the diagnosis of serrated polyps of the large bowel , 2009, Histopathology.

[26]  Michal A. Kurowski,et al.  Transcriptome Profile of Human Colorectal Adenomas , 2007, Molecular Cancer Research.

[27]  J. Jass.  Classification of colorectal cancer based on correlation of clinical, morphological and molecular features , 2007, Histopathology.

[28]  J. Bond,et al.  Microsatellite instability in interval colon cancers. , 2006, Gastroenterology.

[29]  M. O'brien,et al.  Comparison of Microsatellite Instability, CpG Island Methylation Phenotype, BRAF and KRAS Status in Serrated Polyps and Traditional Adenomas Indicates Separate Pathways to Distinct Colorectal Carcinoma End Points , 2006, The American journal of surgical pathology.

[30]  J. Jass,et al.  Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a ‘fusion’ pathway to colorectal cancer , 2006, Histopathology.

[31]  R. Wolff,et al.  Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. , 2005, Gastroenterology.

[32]  B. Leggett,et al.  DNA microsatellite instability in hyperplastic polyps, serrated adenomas, and mixed polyps: a mild mutator pathway for colorectal cancer? , 1999, Journal of clinical pathology.

[33]  P. Laird,et al.  Association between molecular subtypes of colorectal cancer and patient survival. , 2015, Gastroenterology.